Efalizumab-induced guttate psoriasis. Successful management and re-treatment

Journal of Dermatological Treatment

Volumn 19, Issue 3, 2008, Pages 182-184

  Balato, Anna ^a   La Bella, Serena ^a   Gaudiello, Francesca ^a   Balato, Nicola ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Efalizumab; Guttate psoriasis; Psoriasis; Re treatment

Indexed keywords

COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; EFALIZUMAB; ETRETIN;

ADULT; ANAMNESIS; ARTICLE; BODY SURFACE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS GUTTATA; PSORIASIS VULGARIS; PUNCH BIOPSY; REMISSION; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULIN TEST; ULTRAVIOLET B RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; MALE; PSORIASIS; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 45849127266     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701691236     Document Type: Article

References (12)

1. Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): Mechanisms of action. Dermatology. 2004;208:297-306.
2. Costanzo A, Peris K, Talamonti M, Di Cesare A, Fargnoli MC, Botti E, et al. Long-term treatment of plaque psoriasis with efalizumab: An Italian experience. Br J Dermatol. 2007;156:17-23.
3. Debertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006;155:170-81.
4. Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial. Int J Dermatol. 2006;45:605-14.
5. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-8.
6. De Jong EM. The course of psoriasis. Clin Dermatol. 1997;15:687-92.
7. Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corp; 2004.
8. Raptiva (efalizumab) [package insert]. South San Francisco, CA: Genentech Inc; 2005.
9. Griffiths CE, Clark CM, Chalmers RJ, Li Wan PA, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4:1-125.
10. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. 2002;25:913-27.
11. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, et al. Relapse, rebound, and psoriasis adverse events: An advisory group report. J Am Acad Dermatol. 2006;54:171-81.
12. Gisondi P, Giglio MD, Girolomoni G. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: A case study. J Dermatolog Treat. 2006;17:172-5.